More about

Head And Neck Cancer

News
April 28, 2022
2 min read
Save

Interventions reduce opioid prescribing after neck dissection for thyroid cancer

Interventions reduce opioid prescribing after neck dissection for thyroid cancer

DALLAS — Preoperative counseling and perioperative pain management strategies significantly reduced opioid prescriptions at discharge for patients who underwent lateral neck dissection for thyroid cancer, according to study results.

News
April 28, 2022
3 min read
Save

Factors predict survival after immunotherapy combination for HNSCC

Factors predict survival after immunotherapy combination for HNSCC

DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.

News
April 28, 2022
3 min read
Save

Neoadjuvant pembrolizumab does not increase surgical complications in oral cavity cancer

Neoadjuvant pembrolizumab does not increase surgical complications in oral cavity cancer

DALLAS — Neoadjuvant pembrolizumab did not increase risk for serious surgical complications among patients with advanced oral cavity cancer, study results presented at American Head & Neck Society Annual Meeting showed.

News
April 27, 2022
3 min read
Save

Immunotherapy before head and neck cancer surgery does not increase complications

Immunotherapy before head and neck cancer surgery does not increase complications

DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.

News
April 21, 2022
3 min read
Save

Tislelizumab regimen confers clinically meaningful PFS benefit in nasopharyngeal cancer

Tislelizumab regimen confers clinically meaningful PFS benefit in nasopharyngeal cancer

The addition of tislelizumab to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer, according to updated results of the randomized phase 3 RATIONALE-309 study.

News
April 20, 2022
3 min read
Save

Bispecific antibody shows durable benefit in advanced solid tumors

Bispecific antibody shows durable benefit in advanced solid tumors

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

News
April 09, 2022
1 min read
Save

Research spotlight: Innovative strategies guide head and neck cancer treatment

Research spotlight: Innovative strategies guide head and neck cancer treatment

April is Head and Neck Cancer Awareness Month.

News
April 05, 2022
3 min read
Save

Immunotherapy safe within 90 days of radiation therapy for patients with cancer

Immunotherapy safe within 90 days of radiation therapy for patients with cancer

Use of an immune checkpoint inhibitor within 90 days of radiation therapy did not increase risk for serious adverse events among patients with cancer, according to a pooled analysis of prospective trial data published in JAMA Oncology.

News
March 11, 2022
2 min read
Save

Thyroidectomy without radioiodine noninferior for patients with low-risk thyroid cancer

Thyroidectomy without radioiodine noninferior for patients with low-risk thyroid cancer

A follow-up strategy without radioiodine appeared noninferior to an ablation strategy with radioiodine among patients with low-risk thyroid cancer undergoing thyroidectomy, according to study results in The New England Journal of Medicine.

News
February 25, 2022
2 min read
Save

AI platform predicts thyroid cancer, pathologic stage, BRAF status using ultrasound images

AI platform predicts thyroid cancer, pathologic stage, <i>BRAF</i> status using ultrasound images

An artificial intelligence platform predicted thyroid cancer with high accuracy based on analysis of routine ultrasound images, according to study results presented at Multidisciplinary Head and Neck Cancers Symposium.

View more